Enrique Barrajon

Enrique Barrajon

Auto-generated profile, based on publicly available information

Enrique Barrajon

Hospital Clínica Benidorm

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 June 2012 in Supportive Care in Cancer
Verified
Journal Article
Closed access
PDF file
RBRosa Mª Baños
Rosa Mª Baños
MEMacarena Espinoza
Macarena Espinoza
AGAzucena García-Palacios
Azucena García-Palacios
JCJosé M. Cervera
José M. Cervera
GEGaspar Esquerdo
Gaspar Esquerdo
CBCristina Botella
Cristina Botella

1 September 2018 in European Journal of Cancer
Verified
Journal Article
Closed access
EAE. Aranda
E. Aranda
PGP. García-Alfonso
P. García-Alfonso
MBM. Benavides
M. Benavides
ARA. Sánchez Ruiz
A. Sánchez Ruiz
CPCARMEN GUILLEN PONCE
CARMEN GUILLEN PONCE
EDE. Díaz-Rubio
E. Díaz-Rubio

1 October 1989 in American Journal of Clinical Oncology
Verified
Journal Article
Closed access
OHO. Fernández Hidalgo
O. Fernández Hidalgo
FGF. González
F. González
AGA. Gil
A. Gil
WCW. Campbell
W. Campbell
EBE. Barrajón
E. Barrajón
ALA. J. Lacave
A. J. Lacave
Thirty-six patients with metastatic breast cancer, 23 with documented progression of the disease after first-line chemotherapy (CAP or CMF) and 13 without prior chemotherapy, were treated with a simultaneous 120-h infusion of cisplatin (CDDP) and 5-fluorouracil (5-FU). Objective response was demonstrated in 19 patients (52.7%), stable disease in 7 patients (19.4%) and progression of the disease in 10 patients (27.7%). Similar response rate was observed according to tumor site (soft tissues, 50%; bone, 52%; lung, 63%; liver, 55%; and pleura and peritoneum, 42%) and previous treatment (previous chemotherapy, 48%; previously untreated, 61%;). Median duration of response was 8 months. Toxicity was characterized by stomatitis and myelodepression and required dose adjustments in 30% of patients. CDDP and 5-FU infusion deserve further investigation because it appeared to have substantial activity in this preliminary study in metastatic breast cancer.

1 January 2012
Verified
Book Chapter
Closed access
PDF file
EMEspinoza Macarena
Espinoza Macarena
BMBaÑOs Rosa M.
BaÑOs Rosa M.
AGAzucena García-Palacios
Azucena García-Palacios
CMCervera JosÉ M.
Cervera JosÉ M.
EGEsquerdo Gaspar
Esquerdo Gaspar
CBCristina Botella
Cristina Botella
Introduction. In Psycho-oncology, VR has been utilized mainly to manage pain and distress associated to medical procedures and chemotherapy, with very few applications aimed at promotion of wellbeing in hospitalized patients. Considering this, it was implemented a psychological intervention that uses VR to induce positive emotions on adult oncology inpatients with the purpose of evaluating its utility to improve emotional wellbeing in this population.

13 June 2000 in Supportive Care in Cancer
Verified
Journal Article
Closed access
PDF file
EBE. Barrajon
E. Barrajon
RPRamon de Las Peñas
Ramon de Las Peñas

20 May 2019 in Journal of Clinical Oncology
Verified
Journal Article
Open access
EBEnrique Barrajon
Enrique Barrajon
LBLaura Barrajon
Laura Barrajon
E18188 Background: Survival Kaplan-Meier analysis represents the most objective measure of treatment efficacy in oncology, though subjected to potential bias which is worrisome in an era of precision medicine. Independent of the bias inherent to the design of clinical trials, bias may be the result of patient censoring, or incomplete observation. Unlike disease/progression free survival, overall survival is based on a well defined time point and thus avoids interval censoring, but it is our claim that right censoring, due to incomplete follow-up, may still be a source of bias. Methods: The R version 3.5.1 language and the integrated development environment RStudio were used for simulations and survival analysis with the survival package and their available datasets . Survival time was simulated according to a Weibull model with 2 parameters, shape and scale, that determine the event time for every case. Three types of right censoring mechanisms are considered and analyzed independently: 1) case censoring, in which a random number of cases are censored, and the resulting survival time is shortened by a random amount, 2) time censoring, in which a random censoring time variable is applied if and only if it is shorter than the event time, and 3) interim censoring, where a random time variable determines the case inclusion time since the start of trial, and a fixed cutt-off time determines if every case is censored (if the cutt-off time is shorter the the inclusion time plus the event time) or not. For every censoring mechanism, 100 trials was simulated with a 1000 uncensored cases arm and 1000 censored cases arm, in such a way that a censoring Cox hazard ratio (cHR) may be estimated for every trial. An interactive app showing the right censoring effect is presented. Results: A bias index (BI) was buit based on the survival time of event and censored cases. Case censoring was associated with higher BI (mean = 1.75, SD = 0.29) than time censoring (mean = 1.15, SD = 0.19, p = 2.02e-30) and interim censoring (mean = 0.72, SD = 0.21, p = 3.46e-34). It was found an inverse relationship between the censoring proportion and the cHR in case censoring (r = -0.86). Of all the available datasets, the Veterans' Administration Lung Cancer study showed a bias of 1.83, suggesting case censoring bias in both treatment arms. Conclusions: Based in the results of this study it is suggested that: 1) Final results should include all the events in the defined period of interest, 2) a bias index may help in detecting potential bias and correct estimated survival. Censoring bias analysis is planned in recent clinical trials.